{"entity":{"id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","aka":["OMAHA-003"],"tldr":"A phase 3 trial testing Opevesostat in prostate cancer, now recruiting.","summary":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) is a phase 3 interventional study registered as NCT06136624, led by Merck Sharp & Dohme, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003). Planned enrolment is 1310 participants (estimated). The study started in 2023-12-31 and primary completion is expected in 2028-08-02. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06136624","url":"https://clinicaltrials.gov/study/NCT06136624"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["opevesostat"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06136624","phase":"3","setting":"A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)","sponsor":"Merck Sharp & Dohme","participation":[{"nct":"NCT06136624","source":"https://clinicaltrials.gov/study/NCT06136624","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"90ab9f062a88e085fe80f2facf8bd5d1727553676bcf980010fa42e2ca2075e5","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1310,"enrolmentType":"ESTIMATED","siteCount":288,"recruitingSiteCount":236,"countries":["Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Puerto Rico","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2023-12-31","startedType":"actual","enrolled":1310,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06136624/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}